PHILADELPHIA--(BUSINESS WIRE)--Lannett Company, Inc. (AMEX:LCI - News), a manufacturer of generic pharmaceuticals, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Rifampin Capsules in 150 mg and 300 mg, the generic equivalent of Rifadin® Capsules marketed by Sanofi Aventis US, LLC.
